{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:09:52Z","timestamp":1774602592452,"version":"3.50.1"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Garenoxacin (T-3811ME, BMS-284756) is a novel, broad-spectrum des-F(6) quinolone currently under study for the treatment of community-acquired respiratory tract infections. This analysis assessed garenoxacin population pharmacokinetics and exposure-response relationships for safety (adverse effects [AE]) and antimicrobial activity (clinical cure and bacteriologic eradication of<jats:italic>Streptococcus pneumoniae<\/jats:italic>and the grouping of<jats:italic>Haemophilus influenzae<\/jats:italic>,<jats:italic>Haemophilus parainfluenzae<\/jats:italic>, and<jats:italic>Moraxella catarrhalis<\/jats:italic>). Data were obtained from three phase II clinical trials of garenoxacin administered orally as 400 mg once daily for 5 to 10 days for the treatment of community-acquired pneumonia, acute exacerbation of chronic bronchitis, and sinusitis. Samples were taken from each patient before drug administration, 2 h following administration of the first dose, and on the day 3 to 5 visit. Individual Bayesian estimates of the<jats:italic>fu<\/jats:italic>(fraction unbound), the<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>, and the<jats:italic>fu<\/jats:italic>for the area under the concentration-time curve from 0 to 24 h (<jats:italic>fu<\/jats:italic>AUC<jats:sub>0-24<\/jats:sub>) were calculated as measurements of drug exposure by using an ex vivo assessment of average protein binding. Regression analysis was performed to examine the following relationships: treatment-emergent AE incidence and AUC<jats:sub>0-24<\/jats:sub>,<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>, or patient factors; clinical response or bacterial eradication and drug exposure (<jats:italic>fu C<\/jats:italic><jats:sub>max<\/jats:sub>\/MIC,<jats:italic>fu<\/jats:italic>AUC<jats:sub>0-24<\/jats:sub>\/MIC, and other exposure covariates); or disease and patient factors. Garenoxacin pharmacokinetics were described by a one-compartment model with first-order absorption and elimination. Clearance was dependent on creatinine clearance, ideal body weight, age, obesity, and concomitant use of pseudoephedrine. The volume of distribution was dependent on weight and gender. Patients with mild or moderate renal dysfunction had, on average, approximately a 16 or 26% decrease in clearance, respectively, compared to patients of the same gender and obesity classification with normal renal function. AE occurrence was not related to garenoxacin exposure. Overall, clinical cure and bacterial eradication rates were 91 and 90%, respectively, for<jats:italic>S. pneumoniae<\/jats:italic>and 93 and 92%, respectively, for the grouping of<jats:italic>H. influenzae<\/jats:italic>,<jats:italic>H. parainfluenzae<\/jats:italic>, and<jats:italic>M. catarrhalis<\/jats:italic>. The<jats:italic>fu<\/jats:italic>AUC<jats:sub>0-24<\/jats:sub>\/MIC ratios were high (&gt;90% were &gt;200), and none of the pharmacokinetic-pharmacodynamic exposure measurements indexed to the MIC or other factors were significant predictors of clinical or bacteriologic response. Garenoxacin clearance was primarily related to creatinine clearance and ideal body weight. Although garenoxacin exposure was approximately 25% higher for patients with moderate renal dysfunction, this increase does not appear to be clinically significant as exposures in this patient population were not significant predictors of AE occurrence. Garenoxacin exposures were at the upper end of the exposure-response curves for measurements of antimicrobial activity, suggesting that 400 mg of garenoxacin once daily is a safe and adequate dose for the treatment of the specified community-acquired respiratory tract infections.<\/jats:p>","DOI":"10.1128\/aac.48.12.4766-4777.2004","type":"journal-article","created":{"date-parts":[[2004,11,24]],"date-time":"2004-11-24T03:00:46Z","timestamp":1101265246000},"page":"4766-4777","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":41,"title":["Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections"],"prefix":"10.1128","volume":"48","author":[{"given":"Scott","family":"Van Wart","sequence":"first","affiliation":[{"name":"Cognigen Corporation, Buffalo, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luann","family":"Phillips","sequence":"additional","affiliation":[{"name":"Cognigen Corporation, Buffalo, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Cognigen Corporation, Buffalo, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Clinical Discovery, Drug Discovery and Exploratory Development, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diptee A.","family":"Gajjar","sequence":"additional","affiliation":[{"name":"Department of Clinical Discovery, Drug Discovery and Exploratory Development, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akintunde","family":"Bello","sequence":"additional","affiliation":[{"name":"Department of Clinical Discovery, Drug Discovery and Exploratory Development, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Cognigen Corporation, Buffalo, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Cognigen Corporation, Buffalo, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaddeus H.","family":"Grasela","sequence":"additional","affiliation":[{"name":"Cognigen Corporation, Buffalo, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Echols","sequence":"additional","affiliation":[{"name":"Department of Clinical Discovery, Drug Discovery and Exploratory Development, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis M.","family":"Grasela","sequence":"additional","affiliation":[{"name":"Department of Clinical Discovery, Drug Discovery and Exploratory Development, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2793-2797.2001"},{"key":"e_1_3_2_3_2","first-page":"1304","year":"2002","unstructured":"American Society of Health-System Pharmacists, Inc. 2002. American hospital formulary service drug information, p. 1304. Bethesda, Md.","journal-title":"American hospital formulary service drug information"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.5.1418"},{"key":"e_1_3_2_5_2","unstructured":"Bayer Corporation. 2001. Avelox (moxifloxacin) product information. Bayer Corporation West Haven Conn."},{"key":"e_1_3_2_6_2","first-page":"S77","volume":"152","year":"1995","unstructured":"Celli, B. R., G. L. Snider, J. Heffner, et al. 1995. American Thoracic Society statement\u2014standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.152:S77-S120.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_9_2","first-page":"10","year":"2002","unstructured":"Craig, W.A. 2002. Pharmacodynamics of antimicrobials: general concepts and applications, p. 10. In C. H. Nightingale, T. Murakawa, and P. G. Ambrose (ed.). Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker, Inc., New York, N.Y.","journal-title":"Antimicrobial pharmacodynamics in theory and clinical practice"},{"key":"e_1_3_2_10_2","first-page":"841","volume":"38","year":"1981","unstructured":"Dionne, R. E., L. A. Bauer, G. A. Gibson, W. O. Griffen, and R. A. Blouin. 1981. Estimating creatinine clearance in morbidly obese patients. Am. J. Hosp. Pharm.38:841-844.","journal-title":"Am. J. Hosp. Pharm."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.483"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3351-3356.2000"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2256-2263.2003"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1592\/phco.22.3.160.33556","volume":"22","year":"2002","unstructured":"Gajjar, D. A., S. C. Sukoneck, A. Bello, Z. Ge, L. Christopher, and D. M. Grasela. 2002. Effect of a high fat meal on the pharmacokinetics of the des-6(F) quinolone BMS-284756. Pharmacotherapy22:160-165.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Gibaldi M. D. Perrier. 1982. Pharmacokinetics 2nd edition. Marcel Dekker Inc. New York N.Y.","DOI":"10.1201\/b14095"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0149-2918(00)83066-0","volume":"22","year":"2000","unstructured":"Heyd, A., and D. Haverstock. 2000. Retrospective analysis of the safety profile of oral and intravenous ciprofloxacin in a geriatric population. Clin. Ther.22:1239-1250.","journal-title":"Clin. Ther."},{"key":"e_1_3_2_18_2","first-page":"586","volume":"45","year":"2001","unstructured":"Hoellman, D. B., L. M. Kelly, M. R. Jacobs, and P. C. Applebaum. 2001. Comparative antianaerobic activity of BMS-284756. Antimicrob. Agents Chemother.45:586-592.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.672"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1023\/A:1007574217260","volume":"17","year":"2000","unstructured":"Lesko, L. J., M. Rowland, C. C. Peck, and T. F. Blaschke. 2000. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm. Res.17:1335-1344.","journal-title":"Pharm. Res."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg017"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.69-74.2002"},{"key":"e_1_3_2_23_2","first-page":"79","volume":"43","year":"1999","unstructured":"Lister, P. D., and C. C. Sanders. 1999. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. 1999. J. Antimicrob. Chemother.43:79-86.","journal-title":"1999. J. Antimicrob. Chemother."},{"key":"e_1_3_2_24_2","first-page":"1","year":"1992","unstructured":"Matzke, G. R., and S. P. Millikin. 1992. Influence of renal function and dialysis on drug disposition, p. 1-49. In W. J. Jusko, W. E. Evans, and J. J. Schentag (ed.), Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Applied Therapeutics, Inc., Vancouver, Wash.","journal-title":"Applied pharmacokinetics: principles of therapeutic drug monitoring"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","volume":"18","year":"1998","unstructured":"Michalets, E. L. 1998. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy18:84-112.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_2_26_2","unstructured":"National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing. Standard M100-S8. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1630-1635.2003"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00009-2"},{"key":"e_1_3_2_29_2","first-page":"138","year":"1994","unstructured":"NONMEM Project Group. 1994. Part 5, p. 138-139. In S. L. Beal and L. B. Sheiner (ed.), NONMEM user's guide. University of California at San Francisco.","journal-title":"NONMEM user's guide"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2165\/00003088-199631050-00004","volume":"31","year":"1996","unstructured":"Ozdemir, V., J. Fourie, U. Busto, and C. A. Naranjo. 1996. Pharmacokinetic changes in the elderly. Clin. Pharmacokinet.31:372-385.","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_2_31_2","first-page":"80","year":"1989","unstructured":"Peck, C. C., and M. G. Murphy. 1989. Bedside estimation of ideal body weight, p. 80. In C. C. Peck and M. G. Murphy (ed.), Bedside clinical pharmacokinetics: simple techniques for individualizing drug therapy. Applied Therapeutics, Inc., Vancouver, Wash.","journal-title":"Bedside clinical pharmacokinetics: simple techniques for individualizing drug therapy"},{"key":"e_1_3_2_32_2","first-page":"40","year":"2001","unstructured":"Piscitelli, S.C., and K. A. Struble. 2001. Drug interactions with antiretrovirals for HIV infection, p. 40. In S. C. Piscitelli and K. A. Rodvold (ed.), Drug interactions in infectious diseases. Humana Press, Totowa, N.J.","journal-title":"Drug interactions in infectious diseases"},{"key":"e_1_3_2_33_2","first-page":"503","volume":"9","year":"1989","unstructured":"Sheiner, L. B., and S. L. Beal. 1989. Scientific commentary: some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm.9:503-511.","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"e_1_3_2_34_2","first-page":"398","year":"2000","unstructured":"Stahlmann, R., and H. Lode. 2000. Safety overview: toxicity, adverse effects and drug interactions, p. 398-442. In V. Andriole (ed.), The quinolones, 3rd edition. Academic Press, San Diego, Calif.","journal-title":"The quinolones"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.12.4766-4777.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.12.4766-4777.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T12:28:20Z","timestamp":1682857700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.12.4766-4777.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1128\/AAC.48.12.4766-4777.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.12.4766-4777.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]},"assertion":[{"value":"2003-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-07-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}